Innovent Biologics: IBI363 first-line visibility and oral GLP-1 execution are key watchpoints

Overview

This report is Goldman Sachs' meeting note on Innovent Biologics following the 2026 China Healthcare Corporate Day, focusing on management's latest comments on Mazdutide, oral GLP-1, first-line indication development for IBI363, and the PFE collaboration transaction. The overall tone is positive, the report maintains a Buy rating, and assigns a HK$107.04 target price based on risk-adjusted DCF.

Core views

The core view is that Innovent Biologics' near- to medium-term investment story continues to be driven by two main themes: metabolism and oncology. On the one hand, the Mazdutide sales target remains on track, and with NRDL negotiation pricing likely anchored to tirzepatide, patient price sensitivity may ease; on the other hand, if IBI3032's global Phase II design adopts an active comparator and a one-year treatment period, it could provide strong support for a future end-of-Phase-II meeting with the FDA. On the oncology side, Phase III plans for IBI363 in first-line NSCLC and CRC still await confirmation from the internal POC review, while the PFE collaboration enhances the global potential of the early-stage oncology pipeline.

Analysis framework

The report uses a meeting-note style analytical approach, breaking management commentary into four categories: sales progress, clinical development milestones, collaboration transaction progress, and valuation risks, and evaluates the impact on the share price in conjunction with Goldman Sachs' existing Buy rating, DCF target price, and key risk framework.

Methodology notes

• Valuation methodsRisk-adjusted DCF

  12-month target price

  Goldman Sachs uses a risk-adjusted DCF valuation with a 10% discount rate and a 3% terminal growth rate, arriving at a 12-month target price of HK$107.04 for Innovent Biologics.

• Meeting NotesManagement Key Takeaway Summary

  Corporate Day management update

  The report is based primarily on management remarks at China Healthcare Corporate Day 2026, summarizing key items such as Mazdutide sales, IBI3032 Phase II design, IBI363 POC review, and the closing of the PFE collaboration.

• Factor FrameworkGS Factor Profile

  Growth, financial returns, valuation multiples, and composite factors

  The appendix notes that Goldman Sachs compares stocks versus the market and industry peers using growth, financial returns, valuation multiples, and composite indicators, but this framework is not a primary driver of the core investment conclusion in this report.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Innovent Biologics (1801.HK)

  Covered company and investment target in the report

  Strengths

  Buy rating, target price above the disclosed share price, and clear advancement milestones for both metabolic and oncology pipelines.

  Weaknesses

  Core products and drug candidates still rely on delivery in clinical development, NRDL negotiations, and commercialization execution.

  Comparison

  The report places it within the China biopharma coverage universe and includes it alongside multiple Chinese innovative drug companies in the rating comparison set.

  Risks

  Competition in the PD-1/L1 market, uncertainty in approval timing, R&D failures, and safety-related restrictions.

• Mazdutide

  Commercialized metabolic disease product and a key driver of 2027 revenue growth

  Strengths

  Management said it ranked highly during the 618 shopping festival and reiterated the 2027 sales target of Rmb4-5bn.

  Weaknesses

  Sales delivery remains affected by online drug regulation, NRDL negotiation pricing, and patients' willingness to pay.

  Comparison

  With NRDL pricing anchored to tirzepatide, management believes the weight-loss advantage of multi-target GLP-1 will be more readily recognized after the price reduction.

  Risks

  If NRDL pricing, the competitive landscape, or the regulatory environment falls short of expectations, the sales target may come under pressure.

• IBI3032

  Oral small-molecule GLP-1 candidate drug

  Strengths

  Early Phase I data showed 4-week placebo-adjusted weight loss of -8.6%, with manageable safety.

  Weaknesses

  It is still at an early stage, with dose optimization and global Phase II design still in progress.

  Comparison

  The proposed Phase II may include active comparators such as orforglipron or oral Wegovy, setting a higher bar than a simple placebo-controlled design.

  Risks

  If Phase II efficacy, safety, dose selection, or comparison versus competitors is unsatisfactory, the global development value could be weakened.

• IBI363

  Core oncology candidate and key determinant of Phase III visibility in first-line NSCLC/CRC

  Strengths

  Positive data in first-line NSCLC were disclosed at ASCO2026, and patients have already been enrolled into the randomized control arm.

  Weaknesses

  Global Phase III design still awaits the POC data review from late 2026 to early 2027.

  Comparison

  The first-line NSCLC regimen is compared against the Keytruda/chemotherapy combination, while the first-line CRC regimen is compared against beva/chemotherapy.

  Risks

  If POC data, dose regimen, regulatory communication, or coordination with Takeda fall short of expectations, Phase III advancement will be affected.

Key data

• Report Date2026-06-26Goldman Sachs equity research report, published in the evening Hong Kong time.
• Rating and Target PriceBuy；HK$107.04The target price is based on risk-adjusted DCF, using a 10% discount rate and a 3% terminal growth rate.
• Disclosed Share PriceHK$75.15This implies about 42.4% price upside versus the target price.
• Mazdutide 2027 Sales TargetRmb4-5bnManagement reiterated confidence in achieving RMB4bn to RMB5bn of sales in 2027.
• Tirzepatide Price ReferenceStarting dose cut from Rmb1,200 to Rmb230; 5mg around Rmb550Management expects the T2D NRDL negotiation target price to reference tirzepatide.
• IBI3032 Phase I Data4-week placebo-adjusted weight loss of -8.6%; vomiting rate 8%The company plans to initiate a global Phase II study between late 2026 and early 2027, potentially including an active comparator arm.
• IBI363 First-line Indication MilestonesInternal POC review from late 2026 to early 2027; global Phase III planned for 2027Phase III design for first-line NSCLC and CRC depends on POC data jointly reviewed with Takeda.
• PFE Collaboration AmountUS$10.5bnThe early-stage oncology pipeline collaboration is expected to officially close in the third quarter, and management does not foresee major regulatory obstacles.

Impact & implications

For investors, the report reinforces the medium-term catalyst thesis for Innovent Biologics across both metabolic drugs and innovative oncology drugs. Mazdutide's sales delivery and the eventual NRDL pricing outcome will affect revenue visibility; if IBI3032's Phase II design meets a high standard, it could enhance the credibility of its global development; and the POC review for IBI363 is the key clinical milestone determining Phase III visibility in first-line indications. The PFE collaboration helps validate the external value of the company's early-stage oncology pipeline, but investors still need to watch the closing and subsequent co-development execution.

Risks

• Competition in China's PD-1/L1 market is intensifying.
• There is uncertainty around approval timing for key drug candidates.
• Any safety issues could lead to restrictions on off-label use.
• Failure of R&D programs could weaken pipeline value.
• If subsequent clinical design and data readouts for oral GLP-1 and IBI363 fall short of expectations, valuation could be affected.

What to watch

• Mazdutide's subsequent sales ramp-up and progress toward achieving the 2027 Rmb4-5bn target.
• The T2D NRDL negotiation price at the end of 2026 and its pricing outcome relative to tirzepatide.
• IBI3032 dose optimization, global Phase II start timing, and active comparator setup.
• The POC review results for IBI363 in first-line NSCLC and CRC from late 2026 to early 2027.
• Progress of the MarsLight-11 handoff in IO-resistant NSCLC and regulatory clearance for the nsqNSCLC Phase III study.
• Whether the PFE US$10.5bn collaboration can close as expected in the third quarter.